07 Jan / 22
Absci Announces Research Collaboration with Merck
Collaboration to leverage Absci’s Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technologies VANCOUVER, Wash., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the
05 Jan / 22
Absci to Participate in the 40th Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming